Key Takeaways Face/neck consistently show the best repigmentation with tacrolimus 0.1%; early perifollicular islands predict response. Acral (hands/feet) and longstanding […]
Key Takeaways Wood’s lamp: vitiligo shows bright chalk-white fluorescence with sharp borders; early lesions highlight margins before clinical contrast is
Key Takeaways Targeted 308 nm is effective for limited facial/neck lesions and expanding edges of patches. Acral sites (hands/feet) respond slower;
Key Takeaways Backbone therapy for generalized/nonsegmental vitiligo with best responses on face/neck; acral lesions remain hardest. Typical schedules: 2–3×/week, incremental
Key Takeaways Lesional epidermis often shows reduced catalase activity and increased H2O2, contributing to melanocyte stress and antigen exposure. Systemic
Key Takeaways IFN-γ induces keratinocyte/immune-cell secretion of CXCL9/10, recruiting CXCR3+ cytotoxic T cells that kill melanocytes. CD8+ TRM persist in
Key Takeaways Tofacitinib (JAK1/3 inhibitor) has shown facial repigmentation in multiple case series; responses improve with concurrent light (NB-UVB or
Key Takeaways TRuE-V2 confirmed facial repigmentation superiority of ruxolitinib 1.5% cream versus vehicle at ~24 weeks, mirroring TRuE-V1. Continued treatment
Key Takeaways In TRuE-V1, topical ruxolitinib 1.5% cream showed clinically meaningful facial repigmentation versus vehicle by week 24, with continued
Key Takeaways For facial vitiligo, pimecrolimus 1% shows superiority over placebo on F-VASI and global assessments in several RCTs/split-face designs.